Company Overview - UnitedHealth Group Incorporated (UNH) has a market cap of $289 billion and operates globally through four main segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx, providing health benefit plans, care delivery, data and technology services, and pharmacy care solutions [1][2] Stock Performance - Shares of UnitedHealth Group have decreased 48.6% from its 52-week high of $622.83 and are down 36.8% year-to-date (YTD), underperforming the Nasdaq Composite's 18.1% increase [3][4] - Over the past 52 weeks, UNH shares have decreased 47.2%, while the Nasdaq Composite has returned 19.7% [4] - The stock has been trading below its 50-day and 200-day moving averages since last year [4] Recent Financial Results - In Q3 2025, UnitedHealth reported revenue of $113.16 billion, which was weaker than expected, but adjusted EPS of $2.92 beat analyst estimates [5] - The company raised its 2025 adjusted profit forecast to at least $16.25 per share, exceeding prior outlook and analysts' expectations [5] - Management expressed confidence in "durable and accelerating growth" starting in 2026 and noted progress in stabilizing costs, with a medical care ratio (MCR) of 89.9% [5] Analyst Sentiment - Despite the weak stock performance, analysts maintain a moderately optimistic outlook for UnitedHealth, with a consensus rating of "Moderate Buy" from 25 analysts [6] - The mean price target for UNH is $388.64, representing a premium of 21.8% to current levels [6] Competitive Landscape - In comparison, rival Eli Lilly and Company (LLY) has outperformed UNH, with LLY stock surging 40.5% YTD and 43.7% over the past 52 weeks [6]